SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q1 Trading Update

22 Apr 2021 07:00

RNS Number : 2249W
Rentokil Initial PLC
22 April 2021
 

22 April 2021

 

RENTOKIL INITIAL PLC (RTO)

FIRST QUARTER TRADING UPDATE

A strong first quarter, reflecting a strengthening performance in our core Pest Control business supported by continued high growth in Hygiene

 

 

 

(£m)

 

Q1 2021

Growth

 

 

AER

AER

CER

Ongoing Revenue1

 

711.3

12.8%

15.4%

Revenue

 

713.6

12.5%

15.1%

 

Overview of performance (at CER)

We have made a good start to the year, growing Group Ongoing Revenue by 15.4%, of which 9.4% was Organic2 and 6.0% was from acquisitions. Hygiene delivered a 48.5% increase in Ongoing Revenue (up 48.1% Organic), supported by a revenue contribution of £75.7m from one-time disinfection services, reducing, as anticipated, by approximately 25% on the high watermark level of £100m in Q4 2020. Pest Control delivered Ongoing Revenue growth of 10.5% and saw a return to Organic growth of 1.2% in Q1. Recovery in our core businesses, particularly Pest Control, has demonstrated growing momentum over the quarter, and we exited March 2021 with Group Organic growth of 2.5% (excluding disinfection) and Organic growth in Pest Control of 6.3%.

Regional overview (at CER)

North America delivered a very strong performance in Q1, with Ongoing Revenue of £332.6m (an increase of 39.4%), with £263.4m of revenue generated from Pest Control (up 20.7%) and a £53.6m contribution from disinfection services. Trading conditions in our UK & Rest of World operations, which have been severely impacted by lockdowns throughout Q1, are expected to improve significantly over the coming weeks, reflecting progress in the UK's vaccination programme and subsequent easing of lockdown restrictions, and we are therefore expecting performance for the region to rebound strongly in Q2. Our performance in Europe was in line with our expectations for Q1, with Germany, Southern Europe and Latin America (managed out of Europe) in positive growth territory throughout the quarter and with France and Benelux returning to growth in March. The recent reintroduction of lockdowns in parts of Europe, such as France, are likely to result in the recovery of our European markets being several weeks behind the recovery now anticipated in the UK and elsewhere. Our Asia and Pacific regions have also performed as anticipated, with the progress we have seen in Australia and New Zealand supporting our conviction that the lifting of lockdown restrictions is likely to be quickly followed by continued improvements in our core businesses.

Category overview (at CER) 

Our Pest Control category performed very well in Q1, reflecting a return to Organic growth as well as the positive impact of recent acquisitions, including Environmental Pest Service in Florida, completed in Q4 2020. Excluding disinfection, our core Hygiene category declined by 6.2% (down 6.6% Organic) with the pandemic continuing to impact on regular service provision in certain countries, particularly the UK and France. Our core Hygiene operations delivered a significantly improved performance in March (a decline of 3.3%) with positive momentum continuing into April, and we expect a strong recovery in Q2 as trading conditions are anticipated to improve across the majority of our operations. Ongoing Revenue in our Protect & Enhance category declined by 12.3% year on year, held back by ongoing weakness in our Ambius and France Workwear businesses.

M&A

​We signed seven acquisitions in Q1 - six in Pest Control and one in Protect & Enhance (Ambius) - in Australia, Canada, France, Germany, Italy, Spain and Sweden, with combined annualised revenues in the year prior to acquisition of c.£13m. We have built a substantial pipeline of high-quality opportunities and remain confident in our targeted spend of c.£400m in 2021.

Outlook

The ongoing COVID-19 pandemic presents obvious and continued uncertainty. While progress has been made in controlling the virus in certain countries, aided by vaccine roll-out programmes, other countries are seeing rising case numbers and the reintroduction of lockdowns. The path to normality is therefore predicted to be uneven, reflecting regional and country variances, emergence of new strains and vaccine hesitancy. Notwithstanding this, we continue to expect 2021 to be a year of transition with our core services building momentum - as demonstrated by our performance in Q1 - and with disinfection volumes and prices reducing materially from the start of Q2 and leading to a significant unwind as the year progresses.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am very pleased with the performance our colleagues delivered in Q1, in particular the growth momentum achieved by our Pest Control business, and we remain confident in delivering further operational and financial progress in 2021."

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

 

 

 

 

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

 

 

 

 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2020 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKZGZDVMKGMZM
Date   Source Headline
21st May 20267:00 amRNSAppointment of CEO, North America
8th May 202610:30 amRNSHolding(s) in Company
7th May 20264:40 pmRNSResult of AGM
23rd Apr 20264:25 pmRNSFinal Dividend – Pence Sterling Amount Payable
23rd Apr 20262:30 pmRNSIssuance of $500 million 4.625% Notes due 2031
21st Apr 202610:30 amRNSHolding(s) in Company
16th Apr 20267:00 amRNSQ1 Trading Update
15th Apr 20267:00 amRNSDirectorate Change
30th Mar 202610:30 amRNSHolding(s) in Company
26th Mar 20263:46 pmRNSDirector/PDMR Shareholding
25th Mar 202610:50 amRNSAnnual Financial Report
17th Mar 20264:30 pmRNSDirector/PDMR Shareholding
16th Mar 202610:32 amRNSHolding(s) in Company
16th Mar 202610:32 amRNSHolding(s) in Company
12th Mar 202610:30 amRNSHolding(s) in Company
10th Mar 20264:28 pmRNSDirector/PDMR Shareholding
10th Mar 20264:28 pmRNSDirector/PDMR Shareholding
10th Mar 20264:26 pmRNSDirector/PDMR Shareholding
10th Mar 20264:26 pmRNSDirector/PDMR Shareholding
9th Mar 202611:15 amRNSHolding(s) in Company
5th Mar 20267:00 amRNSPreliminary Results
5th Mar 20267:00 amRNSChair Succession Planning Update
23rd Feb 202610:30 amRNSHolding(s) in Company
19th Feb 20262:50 pmRNSDirector Declaration
12th Feb 20265:30 pmRNSNotice of Early Redemption
20th Jan 202610:25 amRNSHolding(s) in Company
19th Jan 202610:30 amRNSHolding(s) in Company
16th Jan 20263:00 pmRNSHolding(s) in Company
14th Jan 202610:30 amRNSHolding(s) in Company
13th Jan 202610:30 amRNSHolding(s) in Company
13th Jan 20267:00 amRNSDirectorate change
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
5th Dec 202510:30 amRNSHolding(s) in Company
5th Dec 202510:30 amRNSHolding(s) in Company
26th Nov 20254:25 pmRNSHolding(s) in Company
28th Oct 202510:45 amRNSHolding(s) in Company
28th Oct 202510:45 amRNSHolding(s) in Company
27th Oct 202510:30 amRNSHolding(s) in Company
23rd Oct 202511:45 amRNSHolding(s) in Company
23rd Oct 20257:00 amRNSQ3 Trading Update
21st Oct 202510:00 amRNSHolding(s) in Company
14th Oct 202510:00 amRNSHolding(s) in Company
1st Oct 202510:30 amRNSBlock listing Interim Review
30th Sep 202510:30 amRNSCompletion of France Workwear business sale
25th Sep 20254:15 pmRNSDirector/PDMR Shareholding
24th Sep 20256:00 pmRNSDirector Declaration
26th Aug 202512:30 pmRNSInterim Dividend – Pence Sterling Amount Payable
7th Aug 202511:10 amRNSHolding(s) in Company
31st Jul 20257:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.